Copyright
©The Author(s) 2018.
World J Gastroenterol. Sep 7, 2018; 24(33): 3770-3775
Published online Sep 7, 2018. doi: 10.3748/wjg.v24.i33.3770
Published online Sep 7, 2018. doi: 10.3748/wjg.v24.i33.3770
Table 1 Patient demographics
Characteristics | All | On beta blockers | Not on beta blockers | P value |
n = 344 | n = 181 (53%) | n = 163 (47%) | ||
Age (yr) | 60 (54-64) | 61 (54-65) | 60 (54-63) | 0.16 |
Female | 35% | 25% | 46% | < 0.001 |
Race/ethnicity | 0.26 | |||
Non-Hispanic White | 57% | 56% | 58% | |
Black | 4% | 3% | 6% | |
Hispanic White | 27% | 30% | 23% | |
Asian | 7% | 5% | 8% | |
Other | 6% | 7% | 5% | |
Etiology of liver disease | 0.39 | |||
Hepatitis C | 50% | 51% | 49% | |
Alcohol | 15% | 15% | 15% | |
Nonalcoholic steatohepatitis | 13% | 15% | 11% | |
Autoimmune/cholestatic | 11% | 9% | 14% | |
Hepatitis B | 4% | 2% | 6% | |
Other | 6% | 7% | 6% | |
HCC | 27% | 32% | 22% | 0.04 |
BMI (kg/m2) | 28.4 (24.9-33.0) | 29.3 (25.8-33.7) | 27.7 (24.2-31.8) | 0.0081 |
Medical co-morbidities | ||||
Hypertension | 44% | 48% | 40% | 0.12 |
Diabetes | 32% | 36% | 27% | 0.06 |
Coronary artery disease | 7% | 10% | 4% | 0.04 |
Lab tests | ||||
Lab MELD | 15 (12-18) | 15 (13-18) | 15 (12-18) | 0.55 |
Total bilirubin (mg/dL) | 2.3 (1.6-3.4) | 2.3 (1.5-3.2) | 2.4 (1.7-3.6) | 0.41 |
INR | 1.4 (1.2-1.6) | 1.4 (1.3-1.6) | 1.4 (1.2-1.6) | 0.54 |
Creatinine (mg/dL) | 0.9 (0.8-1.2) | 1 (0.8-1.2) | 0.9 (0.7-1.2) | 0.0034 |
Sodium (mEq/L) | 137 (134-139) | 137 (135-139) | 137 (134-139) | 0.75 |
Ascites | ||||
Mild-moderate | 30% | 30% | 30% | 0.40 |
Refractory | 3% | 4% | 2% | |
Hepatic encephalopathy1 | 21% | 22% | 21% | 0.86 |
Child Pugh Score | 0.89 | |||
A | 19% | 18% | 20% | |
B | 60% | 60% | 59% | |
C | 21% | 22% | 21% |
Table 2 Comparison of metrics of physical frailty by beta-blocker use
Outcome | On beta blockers | Not on beta blockers | P value |
n = 181 (53%) | n = 163 (47%) | ||
Liver frailty index1 | 3.75 (3.37-4.15) | 3.64 (3.23-4.04) | 0.04 |
Chair stands (s) | 12.5 (10-16.2) | 10.9 (8.3-13.2) | 0.003 |
Grip strength (kg) | 33.3 (24.3-40) | 29 (22-37) | 0.03 |
Balance (s) | 30 (30-30) | 30 (26.6-30) | 0.20 |
LFI Frail | 14% | 14% | 0.98 |
LFI Robust | 16% | 25% | 0.06 |
Exhaustion | 51% | 52% | 0.89 |
MNLTPA frailty | 58% | 60% | 0.69 |
Table 3 Competing risks survival analysis
Variable | Univariable SHR (95%CI) | Multivariable SHR (95%CI) |
P value | P value | |
Being on a Beta Blocker | 0.57 (0.38-0.85) | 0.55 (0.36-0.83) |
0.006 | 0.005 | |
Liver Frailty Index | 1.52 (1.13-2.03) | 1.35 (1.02-1.80) |
0.005 | 0.04 | |
MELD score | 1.03 (0.99-1.07) | |
0.19 | ||
Creatinine | 1.17 (1.07-1.28) | 1.10 (1.00-1.22) |
0.001 | 0.006 | |
Albumin | 0.79 (0.56-1.12) | |
0.18 | ||
Sodium | 0.99 (0.95-1.04) | |
0.76 | ||
HCC | 0.80 (0.50-1.29) | |
0.37 | ||
Ascites | 0.98 (0.63-1.51) | |
0.92 | ||
Age | 1.02 (0.99-1.04) | |
0.15 | ||
Gender (female) | 1.09 (0.72-1.65) | |
0.68 | ||
Hepatic encephalopathy | 1.99 (1.30-3.05) | 1.64 (1.05-2.57) |
(> 60 s) | 0.001 | 0.03 |
- Citation: Kuo SZ, Lizaola B, Hayssen H, Lai JC. Beta-blockers and physical frailty in patients with end-stage liver disease. World J Gastroenterol 2018; 24(33): 3770-3775
- URL: https://www.wjgnet.com/1007-9327/full/v24/i33/3770.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i33.3770